Adaptive Biotechnologies Corporation
ADPT
Kedudukan dalam Saham
#4171
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Harga Saham
$24.09
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$3.84B
Perubahan (1 hari)
-5.82%
Perubahan (1 tahun)
47.79%
Negara
US
Perdagangan Adaptive Biotechnologies Corporation (ADPT)
Kategori
Healthcare
Margin Operasi untuk Adaptive Biotechnologies Corporation (ADPT)
Margin Operasi pada October 2026 TTM: -12.16%
Menurut laporan kewangan dan harga saham terkini Adaptive Biotechnologies Corporation, margin operasi semasa (TTM) ialah -12.16%. Pada akhir 2024, margin operasi syarikat ialah -90.83%.
Sejarah Margin Operasi untuk Adaptive Biotechnologies Corporation dari 2017 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | -12.16% | -41.03% |
| 2025 | -20.62% | -77.30% |
| 2024 | -90.83% | -31.88% |
| 2023 | -133.33% | 23.42% |
| 2022 | -108.03% | -20.21% |
| 2021 | -135.39% | -12.84% |
| 2020 | -155.33% | 68.56% |
| 2019 | -92.15% | 3.09% |
| 2018 | -89.39% | -22.73% |
| 2017 | -115.68% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -103.17% |
US
|
|
| -149.01% | -87.75% |
US
|
|
| 25.57% | -102.10% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -102.37% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.